Large Outflow of Money Witnessed in St. Jude Medical

St. Jude Medical (STJ) : The total money flow in St. Jude Medical (STJ) was negative ($9.08 million), showing the domination of sellers in the Friday trading session. The traders utilized every rise to sell their positions, as seen in the value of trading on downtick to the tune of $30.61 million. Transactions on upticks were comparatively lower at $21.52 million. The uptick to downtick ratio was 0.7. The total block trades done on upticks were valued at $10.44 million. The total block trades on downticks were valued at $19.58 million. The uptick to the downtick ratio of block trades was 0.53. The money flow during block trades was negative ($9.15 million) when the stock traded with a gain of $14 cent. St. Jude Medical (STJ) was $81.7, an increase of 0.17% over the previous days close.


St. Jude Medical (STJ) : The consensus price target for St. Jude Medical (STJ) is $74.32 for the short term with a standard deviation of $11.88. The most optimist securities analyst among the 17 who monitor the stock believes that the stock can reach $89, however, the pessimist price target for the company is $54.

St. Jude Medical (NYSE:STJ): stock turned positive on Friday. Though the stock opened at $81.4, the bulls momentum made the stock top out at $81.85 level for the day. The stock recorded a low of $81.38 and closed the trading day at $81.7, in the green by 0.17%. The total traded volume for the day was 1,608,899. The stock had closed at $81.56 in the previous days trading.

In a related news, Fecho Jeff, officer (VP, Global Quality) of St Jude Medical Inc, unloaded 10,408 shares at an average price of $51.71 on February 5, 2016. The total amount of the transaction was worth $538,198, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

St. Jude Medical, Inc. develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. Its six principal product categories include tachycardia implantable cardioverter defibrillator (ICD) systems, bradycardia pacemaker systems, atrial fibrillation (AF) products (electrophysiology introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems), vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, heart failure monitoring device and other vascular accessories), structural heart products and neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.